.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Colorcon
Express Scripts
Julphar
McKesson
Covington
Dow
Merck
QuintilesIMS
Deloitte

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:HSPC-sparing treatments for RB-positive abnormal cellular proliferation
Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
Inventor(s): Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Apex, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC)
Assignee: GI Therapeutics, Inc. (Research Triangle Park, NC)
Application Number:14/214,048
Patent Claims:1. A method for the treatment of cancer in a host, wherein the cancer is Retinoblastoma-positive (Rb) and selected from the group consisting of breast cancer, colon cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, and glioblastoma, comprising administering an effective amount of a compound to a host in need thereof, wherein the compound is selected from the group consisting of: ##STR00326## or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the compound is ##STR00327## or its pharmaceutically acceptable salt.

3. The method of claim 1, wherein the compound is ##STR00328## or its pharmaceutically acceptable salt.

4. The method of claim 1, wherein the cancer is breast cancer.

5. The method of claim 1, wherein the cancer is colon cancer.

6. The method of claim 1, wherein the cancer is ovarian cancer.

7. The method of claim 1, wherein the cancer is non-small cell lung cancer.

8. The method of claim 1, wherein the cancer is glioblastoma.

9. The method of claim 1, wherein the host is a human.

10. The method of claim 1, wherein the compound is administered in combination with another chemotherapeutic agent.

11. The method of claim 10, wherein the chemotherapeutic agent does not rely on cellular proliferation for its anti-cancer activity.

12. The method of claim 1, wherein the compound is administered orally.

13. The method of claim 1, wherein the compound is ##STR00329## or a pharmaceutically acceptable salt thereof.

14. The method of claim 1, wherein the compound is ##STR00330## or a pharmaceutically acceptable salt thereof.

15. The method of claim 1, wherein the cancer is prostate cancer.

16. A method for the treatment of Retinoblastoma-positive breast cancer in a host comprising administering an effective amount of a compound to a host in need thereof, wherein the compound is ##STR00331## or a pharmaceutically acceptable salt thereof.

17. The method of claim 16, wherein the host is a human.

18. The method of claim 16, wherein the compound is administered orally.

19. The method of claim 16, wherein the compound is administered in combination with a chemotherapeutic agent.

20. The method of claim 19, wherein the chemotherapeutic agent is an mTOR inhibitor.

21. The method of claim 19, wherein the chemotherapeutic agent is a PI3 kinase inhibitor.

22. The method of claim 19, wherein the chemotherapeutic agent is a dual mTOR-PI3K inhibitor.

23. The method of claim 19, wherein the chemotherapeutic agent is a MEK inhibitor.

24. The method of claim 19, wherein the chemotherapeutic agent is a RAS inhibitor.

25. The method of claim 19, wherein the chemotherapeutic agent is an ALK inhibitor.

26. The method of claim 19, wherein the chemotherapeutic agent is a HSP inhibitor.

27. The method of claim 19, wherein the chemotherapeutic agent is letrozole.

28. The method of claim 19, wherein the chemotherapeutic agent is capecitabine.

29. The method of claim 19, wherein the chemotherapeutic agent is tamoxifen.

30. The method of claim 19, wherein the chemotherapeutic agent is pictilisib.

31. The method of claim 19, wherein the chemotherapeutic agent is buparlisib.

32. The method of claim 19, wherein the chemotherapeutic agent is everolimus.

33. The method of claim 19, wherein the chemotherapeutic agent is goserelin.

34. The method of claim 19, wherein the chemotherapeutic agent is anastrozole.

35. The method of claim 19, wherein the chemotherapeutic agent is doxorubicin.

36. The method of claim 19, wherein the chemotherapeutic agent is paclitaxel.

37. The method of claim 19, wherein the chemotherapeutic agent is a monoclonal antibody which targets the human epidermal growth factor receptor 2 (HER-2).

38. The method of claim 37, wherein the monoclonal antibody is trastuzumab.

39. The method of claim 37, wherein the monoclonal antibody is conjugated with a chemotherapeutic agent.

40. The method of claim 39, wherein the conjugated monoclonal antibody is ado-trastuzumab emtansine.

41. The method of claim 16, wherein the breast cancer is estrogen-receptor positive.

42. A method for the treatment of Retinoblastoma (Rb)-positive prostate cancer in a host comprising administering an effective amount of a compound to a host in need thereof, wherein the compound is ##STR00332## or a pharmaceutically acceptable salt thereof.

43. The method of claim 42, wherein the host is a human.

44. The method of claim 42, wherein the compound is administered orally.

45. The method of claim 42, wherein the compound is administered in combination with a chemotherapeutic agent.

46. The method of claim 45, wherein the chemotherapeutic agent is prednisone.

47. The method of claim 45, wherein the chemotherapeutic agent is docetaxel.

48. The method of claim 45, wherein the chemotherapeutic agent is mitoxantrone.

49. The method of claim 45, wherein the chemotherapeutic agent is bicalutamide.

50. The method of claim 45, wherein the chemotherapeutic agent is flutamide.

51. The method of claim 45, wherein the chemotherapeutic agent is nilutamide.

52. The method of claim 10, wherein the chemotherapeutic agent is an mTOR inhibitor.

53. The method of claim 10, wherein the chemotherapeutic agent is a PI3K inhibitor.

54. The method of claim 10, wherein the chemotherapeutic agent is a dual mTOR-PI3K inhibitor.

55. The method of claim 10, wherein the chemotherapeutic agent is a MEK inhibitor.

56. The method of claim 10, wherein the chemotherapeutic agent is a RAS inhibitor.

57. The method of claim 10, wherein the chemotherapeutic agent is an ALK inhibitor.

58. The method of claim 10, wherein the chemotherapeutic agent is a HSP inhibitor.

59. The method of claim 10, wherein the chemotherapeutic agent is letrozole.

60. The method of claim 10, wherein the chemotherapeutic agent is capecitabine.

61. The method of claim 10, wherein the chemotherapeutic agent is tamoxifen.

62. The method of claim 10, wherein the chemotherapeutic agent is pictilisib.

63. The method of claim 10, wherein the chemotherapeutic agent is buparlisib.

64. The method of claim 10, wherein the chemotherapeutic agent is everolimus.

65. The method of claim 10, wherein the chemotherapeutic agent is goserelin.

66. The method of claim 10, wherein the chemotherapeutic agent is anastrozole.

67. The method of claim 10, wherein the chemotherapeutic agent is doxorubicin.

68. The method of claim 10, wherein the chemotherapeutic agent is paclitaxel.

69. The method of claim 10, wherein the chemotherapeutic agent is prednisone.

70. The method of claim 10, wherein the chemotherapeutic agent is docetaxel.

71. The method of claim 10, wherein the chemotherapeutic agent is mitoxantrone.

72. The method of claim 10, wherein the chemotherapeutic agent is bicalutamide.

73. The method of claim 10, wherein the chemotherapeutic agent is flutamide.

74. The method of claim 10, wherein the chemotherapeutic agent is nilutamide.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe GI Therapeutics, Inc. (Research Triangle Park, NC) Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Apex, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC) ► SubscribeRXOrphansearch
Genentech
KADCYLA
ado-trastuzumab emtansine
VIAL; SINGLE-USE1254270012013-02-22► Subscribe GI Therapeutics, Inc. (Research Triangle Park, NC) Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Apex, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC) ► SubscribeRXsearch
Genentech
KADCYLA
ado-trastuzumab emtansine
VIAL; SINGLE-USE1254270022013-02-22► Subscribe GI Therapeutics, Inc. (Research Triangle Park, NC) Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Apex, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Canada2906156Sep 18, 2014
Canada2906157Sep 18, 2014
Canada2906166Sep 18, 2014
China105407723Mar 16, 2016
China105407889Mar 16, 2016
China105473140Apr 06, 2016
European Patent Office2967050Jan 20, 2016
European Patent Office2967050Sep 28, 2016
European Patent Office2968290Jan 20, 2016
European Patent Office2968290Sep 28, 2016
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Citi
Farmers Insurance
Chubb
Federal Trade Commission
Novartis
Daiichi Sankyo
Cantor Fitzgerald
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot